Atara Biotherapeutics
ATRA
117 hedge funds and large institutions have $1.01B invested in Atara Biotherapeutics in 2019 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 29 reducing their positions, and 15 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 29
33% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 15
21% more capital invested
Capital invested by funds: $833M → $1.01B (+$174M)
4% more funds holding
Funds holding: 112 → 117 (+5)
0.12% more ownership
Funds ownership: 4.39% → 4.52% (+0.12%)
43% less call options, than puts
Call options by funds: $1.22M | Put options by funds: $2.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$24.5M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$5.85M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.81M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$4.62M |
| 5 |
PA
Pinnacle Associates
New York
|
+$4.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
-$13.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.6M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.93M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$5.34M |
ATRA Hedge Fund Activity: Q4 2019 in Review
117 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q4 2019, worth a combined $1.01B — up 21% from $833M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ATRA positions and 15 closed out — a net gain of 5 holders — while 45 added to existing stakes and 29 trimmed.
The largest buyer was Canada Pension Plan Investment Board, adding an estimated $24.5M. The largest seller was Neuberger Berman Group, exiting entirely with an estimated $13.8M sold.
- 117 institutional investors held Atara Biotherapeutics (ATRA) as of Q4 2019, up from 112 in Q3 2019.
- Funds reported $1.01B of Atara Biotherapeutics stock for Q4 2019, up 21% quarter-over-quarter.
- 20 funds opened new Atara Biotherapeutics positions in Q4 2019 and 15 closed out, a net change of +5 holders.
- The largest Atara Biotherapeutics buyer in Q4 2019 was Canada Pension Plan Investment Board, an estimated $24.5M added.
- The largest Atara Biotherapeutics seller in Q4 2019 was Neuberger Berman Group, an estimated $13.8M sold.
Based on aggregated 13F filings for Q4 2019.